Royal Bank of Canada
FULC icon

Royal Bank of Canada’s Fulcrum Therapeutics FULC Stock Holding History

Royal Bank of Canada’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11K Sell
2,827
-24
-0.8% -$146 ﹤0.01% 6621
2026
Q1 		$21K Sell
2,851
-1,256
-31% -$11.7K ﹤0.01% 5879
2025
Q4 		$47K Sell
4,107
-996,742
-100% -$10.1M ﹤0.01% 5586
2025
Q3 		$9.21M Buy
1,000,849
+996,632
+23,634% +$7.21M ﹤0.01% 2205
2025
Q2 		$29K Buy
4,217
+1,656
+65% +$8.86K ﹤0.01% 6138
2025
Q1 		$7K Sell
2,561
-3,266
-56% -$12K ﹤0.01% 6257
2024
Q4 		$28K Sell
5,827
-415
-7% -$1.53K ﹤0.01% 5967
2024
Q3 		$22K Buy
6,242
+298
+5% +$2.21K ﹤0.01% 6068
2024
Q2 		$37K Buy
5,944
+5,936
+74,200% +$45K ﹤0.01% 5787
2024
Q1 		$0 Hold
8
– – ﹤0.01% 7205
2023
Q4 		$0 Sell
8
-2
-20% -$9 ﹤0.01% 7276
2023
Q3 		$0 Hold
10
– – ﹤0.01% 7245
2023
Q2 		$0 Sell
10
-2,884
-100% -$8.47K ﹤0.01% 7387
2023
Q1 		$8K Sell
2,894
-4,757
-62% -$42.6K ﹤0.01% 6406
2022
Q4 		$56K Buy
7,651
+7,216
+1,659% +$47.1K ﹤0.01% 5808
2022
Q3 		$3K Buy
435
+235
+118% +$1.68K ﹤0.01% 6887
2022
Q2 		$1K Sell
200
-1,496
-88% -$14.6K ﹤0.01% 7121
2022
Q1 		$40K Sell
1,696
-2,887
-63% -$40.9K ﹤0.01% 6237
2021
Q4 		$81K Buy
4,583
+1,343
+41% +$26.6K ﹤0.01% 6080
2021
Q3 		$91K Buy
3,240
+1,722
+113% +$32.6K ﹤0.01% 5770
2021
Q2 		$16K Sell
1,518
-168
-10% -$1.7K ﹤0.01% 6676
2021
Q1 		$20K Buy
1,686
+990
+142% +$12.2K ﹤0.01% 6423
2020
Q4 		$8K Buy
696
+673
+2,926% +$7.61K ﹤0.01% 6476
2020
Q3 		$0 Buy
23
+2
+10% +$24 ﹤0.01% 6731
2020
Q2 		$0 Sell
21
-32
-60% -$504 ﹤0.01% 6715
2020
Q1 		$1K Sell
53
-395
-88% -$6.32K ﹤0.01% 6428
2019
Q4 		$7K Buy
448
+162
+57% +$1.55K ﹤0.01% 6248
2019
Q3 		$2K Buy
+286
New +$3.16K ﹤0.01% 6279

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royal Bank of Canada's FULC Position: Q2 2026 in Review

Royal Bank of Canada reduced its Fulcrum Therapeutics (FULC) stake by 0.84% in Q2 2026, selling an estimated $146 and leaving 2,827 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #6621.

Royal Bank of Canada first reported a position in FULC in Q3 2019 and has held it in 28 quarters since. The position peaked at $9.21M in Q3 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Royal Bank of Canada held 2,827 shares of Fulcrum Therapeutics worth $11K as of Q2 2026.
  • Royal Bank of Canada sold 24 Fulcrum Therapeutics shares in Q2 2026, an estimated $146.
  • Fulcrum Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6621 holding.
  • Royal Bank of Canada first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Royal Bank of Canada's Fulcrum Therapeutics position peaked at $9.21M in Q3 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.